Afya Limited — FY2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone Q4 earnings release; the filing does not provide a clear set of Q4-only financial results. Financial statements are audited and prepared under IFRS, with the Brazilian real (R$) as the functional and presentation currency. Comparisons are affected by acquisitions and are not fully like-for-like.
Business context
Afya operates a Brazilian medical-education and digital-health-services platform across undergraduate education, continuing education, and digital services. It reported 66,034 undergraduate students and 84,222 students across all segments at year-end. Its medical-school network had 3,163 approved seats, of which 3,113 were operating. DelRey, acquired in January 2023, contributed 340 medical seats.
Financial and operating performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | R$2,875.9m | R$2,329.1m | +23.5% |
| Gross profit | R$1,766.1m | R$1,469.5m | +20.2% |
| Operating income | R$767.1m | R$664.1m | +15.5% |
| Net income | R$405.4m | R$392.8m | +3.2% |
| Adjusted EBITDA | R$1,165.7m | R$961.9m | +21.2% |
| Operating cash flow | R$1,043.6m | R$843.9m | +23.6% |
| Capital expenditures | R$218.4m | R$318.2m | −31.4% |
Gross margin declined to approximately 61.4% from 63.1%; operating margin to 26.7% from 28.5%; and net margin to 14.1% from 16.9%. Adjusted EBITDA margin was approximately 40.5%, versus 41.3%. Adjusted EBITDA and operating cash conversion are non-IFRS measures; the latter was 97.1%, compared with 94.4%.
- Revenue by segment: Undergrad R$2,511.0m (+23.2%); Continuing Education R$146.8m (+34.9%); Digital Services R$229.3m (+20.7%), before inter-segment eliminations.
- Drivers: Growth reflected the DelRey acquisition, higher medical-seat capacity and tuition pricing, more continuing-education students, and increased digital-services active payers. Management attributed 45.2% of 2023 revenue growth to acquisitions and 54.8% to organic growth.
- Finance costs: Net finance expense increased to R$347.0m from R$247.9m, chiefly reflecting higher interest expense, including on debentures issued in December 2022. This limited net-income growth despite higher revenue and operating income.
- Cash and liquidity: Cash and cash equivalents were R$553.0m at year-end, down from R$1,093.1m. Management said cash and operating cash flows should cover ordinary working-capital needs and capital expenditures for the next 12 months.
- Debt and obligations: Loans and financing totaled R$1,800.8m, including the R$826.0m Series A preferred-share liability and R$529.3m debentures. Lease liabilities were R$874.6m; amounts payable to selling shareholders were R$566.9m. Total undiscounted contractual obligations were R$5,054.6m. The debenture covenant requires net debt to Adjusted EBITDA of no more than 3.0x; Afya reported compliance at year-end.
Material changes, outlook and notable items
- DelRey’s acquisition consideration was R$816.2m. Purchase accounting recognized R$728.8m of identifiable intangible assets and R$75.1m of goodwill. Valuing DelRey’s licenses and customer relationships was the auditor’s critical audit matter, involving forecast and discount-rate assumptions.
- Unigranrio settled an ISS tax matter through an amnesty program, paying R$14.9m. The matter included prior provisions and seller indemnification; a related gain contributed to other income. Adjusted EBITDA excludes a R$16.8m tax-amnesty gain.
- Management budgeted R$257.3m of capital expenditures for 2024, primarily to support business growth and operations. This is a capex budget, not earnings or revenue guidance. Management also estimates a medical-student base of 23,062 by 2030, subject to regulatory compliance and seat maturation.
- Brazil revoked the five-year suspension on authorizing new medical courses in April 2023 and announced a new Mais Médicos public call, creating potential competitive pressure. Afya’s planned capacity growth depends on MEC approvals and maintaining academic and regulatory standards.
- Risks include dependence on medical-course tuition, student payment delays and defaults, FIES payment or rule changes, possible loss or modification of PROUNI tax benefits, inflation and interest-rate exposure, foreign-exchange volatility, and acquisition integration and impairment risk. Digital Services has seasonal revenue patterns, with Medcel generally stronger in the first and fourth quarters.
- Brazil’s constitutional tax reform and proposed changes affecting PROUNI exemptions could affect future taxes; the filing does not quantify the potential impact. The company does not anticipate common-share dividends in the foreseeable future. Its Series A preferred shares carry a cumulative 6.5% annual dividend and senior rights.
- The auditor issued an unqualified opinion on the financial statements and internal controls. DelRey was excluded from the 2023 internal-control assessment while being included in consolidated results; it represented 8.3% of revenue and 19.3% of net income. Management and the auditor otherwise concluded internal control over financial reporting was effective.
Most important facts for investors to verify
- Review the audited statements and notes for debt, preferred-share terms, repayment timing, lease commitments, and the R$134m DelRey installment due in January 2024.
- Assess whether operating cash generation can sustain acquisition spending, planned 2024 capex, and obligations while cash balances have fallen.
- Track medical-seat approvals, occupancy, pricing, enrollment trends, and the potential competitive effect of new medical-course authorizations.
- Evaluate the sustainability of margins and earnings given rising service costs, higher finance expense, credit-loss allowances, and acquisition-related growth.
- Examine DelRey’s purchase-price allocation and the assumptions supporting acquired intangible assets and goodwill, alongside integration progress and impairment testing.
- Monitor changes to PROUNI and FIES, the tax-reform implementation, and related effects on Afya’s effective tax rate and student financing.
- Consider governance and dilution: Bertelsmann controls approximately 63.4% of voting power, while the Series A preferred shares have senior economic rights and potential conversion features.